Sai Parenteral's (NSE:SAIPARENT) Other Current Liabilities: ₹1,259 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SAIPARENT Sai Parenteral's Ltd NSE:SAIPARENT
14 GF Score
Price ₹569.70
! 7 Warning Signs
View Full Analysis

What is Sai Parenteral's Other Current Liabilities?

Sai Parenteral's NSE:SAIPARENT +5.28% 14 Other Current Liabilities is ₹1,259 Mil as of Sep. 2025. GuruFocus rates NSE:SAIPARENT with a GF Score™ of 14/100. The stock has 7 warning signs investors should review.

Sai Parenteral's's other current liabilities for the quarter that ended in Sep. 2025 was ₹1,259 Mil.

Sai Parenteral's's quarterly other current liabilities increased from Mar. 2024 (₹127 Mil) to Mar. 2025 (₹2,037 Mil) but then declined from Mar. 2025 (₹2,037 Mil) to Sep. 2025 (₹1,259 Mil).

Sai Parenteral's's annual other current liabilities increased from Mar. 2023 (₹70 Mil) to Mar. 2024 (₹127 Mil) and increased from Mar. 2024 (₹127 Mil) to Mar. 2025 (₹2,037 Mil).

Sai Parenteral's Other Current Liabilities Related Terms

Sai Parenteral's Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Sai Parenteral's's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sai Parenteral's Other Current Liabilities Chart

Sai Parenteral's Annual Data
Trend Mar23 Mar24 Mar25
Other Current Liabilities
69.70 126.65 2,036.59

Sai Parenteral's Semi-Annual Data
Mar23 Mar24 Mar25 Sep25
Other Current Liabilities 69.70 126.65 2,036.59 1,258.53
NSE:SAIPARENT
14GF Score
Sai Parenteral's Ltd NSE:SAIPARENT
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sai Parenteral's Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of ₹1,259 Mil mean?
Sai Parenteral's (NSE:SAIPARENT) has a Other Current Liabilities of ₹1,259 Mil as of Sep. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Sai Parenteral's.
Is Sai Parenteral's' Other Current Liabilities too high?
Sai Parenteral's' current Other Current Liabilities is ₹1,259 Mil. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' Other Current Liabilities compare to LLY and JNJ?
Sai Parenteral's' Other Current Liabilities of ₹1,259 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Sai Parenteral's. Sai Parenteral's's current Other Current Liabilities is ₹1,259 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (NSE:SAIPARENT) has a current Other Current Liabilities of ₹1,259 Mil. The current Other Current Liabilities is ₹1,259 Mil. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Sai Parenteral's (NSE:SAIPARENT), the current Other Current Liabilities is ₹1,259 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sai Parenteral's Business Description

Other Exchanges 544742:India
Address Plot No 39, 5th floor, Lavanya Arcade Jayabheri Enclave, Gachibowli, K.V.Rangareddy, Seri Lingampally, Hyderabad, TG, IND, 500032
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score

Get the complete analysis for NSE:SAIPARENT

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹569.70
Price